EP3062750B1 - Vernetzungssteuerung - Google Patents

Vernetzungssteuerung Download PDF

Info

Publication number
EP3062750B1
EP3062750B1 EP13788721.2A EP13788721A EP3062750B1 EP 3062750 B1 EP3062750 B1 EP 3062750B1 EP 13788721 A EP13788721 A EP 13788721A EP 3062750 B1 EP3062750 B1 EP 3062750B1
Authority
EP
European Patent Office
Prior art keywords
photosensitizer
control
light
crosslinking
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13788721.2A
Other languages
English (en)
French (fr)
Other versions
EP3062750A1 (de
Inventor
Christof Donitzky
Armin Wellhoefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of EP3062750A1 publication Critical patent/EP3062750A1/de
Application granted granted Critical
Publication of EP3062750B1 publication Critical patent/EP3062750B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/0079—Methods or devices for eye surgery using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00844—Feedback systems
    • A61F2009/00851—Optical coherence topography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00872—Cornea

Definitions

  • the present disclosure generally relates to crosslinking of tissue. More particularly, embodiments of the present disclosure relate to a crosslinking control system, the use of the crosslinking control system, a laser system comprising the crosslinking control system, a crosslinking control method and a method for laser treatment.
  • the human eyeball is bounded by the corneosclera. Due to internal eye pressure, the corneosclera, which contains collagen, has an approximately spherical shape. In the posterior eyeball region, the corneosclera consists of white sclera. The cornea, which is translucent to visible light, is situated in the anterior region.
  • Deformations of the corneosclera can cause ametropia.
  • axial myopia a type of myopia
  • An ellipsoidal shaped corneal surface can cause a form of astigmatism or other high order aberration, which is called "irregular corneal curvature".
  • an excimer or femtosecond laser under certain circumstances (for example, in the case of unstable tissue or an overly thin cornea) it is necessary to stabilize the tissue of the eye before the treatment, to guarantee safe treatment.
  • ectasia Another defect of the cornea can be caused by progressive and irregular changes in corneal shape. This is typically known as ectasia. These ectatic changes are typically marked by corneal thinning and an increase in the anterior and/or posterior curvatures of the cornea, and often lead to high levels of myopia and astigmatism.
  • the most common form of ectasia is keratoconus. Keratoconus, a pathological softening of the cornea, leads to a progressive thinning and cone-shaped deformation of the cornea. As the bulging increases, the cornea becomes typically thinner below the center. It can fracture and become scarred, which can permanently reduce visual acuity. In these conditions, the corneal stroma is structurally weakened and biomechanically unstable.
  • corneal surgery there may be destabilization of the corneal integrity due to photodisruption or photoablation of corneal tissue as well as through mechanical incisions by metal or diamond knifes.
  • Corneal crosslinking (which is also often referred to as corneal cross-linking, corneal collagen crosslinking or corneal collagen cross-linking) is a technique which uses ultraviolet (UV) light or light in the blue spectrum and a photosensitizer to strengthen chemical bonds in the cornea and to thereby increase the corneal stiffness. The stiffening effect results from UV radiation of the photosensitizer. By means of the UV radiation, the photosensitizer is activated to cause corneal crosslinking. Corneal crosslinking involves the cross-linking of collagen fibers.
  • corneal crosslinking may be regarded as the process of placing a photosensitizer onto or into the cornea followed by exposure to UV light, in order to stiffen the cornea.
  • Known techniques for corneal crosslinking and crosslinking control are described in WO 2013/059837 .
  • Crosslinking is generally not limited to applications on or in eye tissue. Rather applications with all kinds of tissue are conceivable, which will herein generally be referred to as crosslinking.
  • corneal crosslinking has been used extensively for stabilizing keratoconic corneas to prevent further progression of this disease.
  • the corneal epithelium is at least partially removed to introduce riboflavin as one example of a photosensitizer into the cornea, because the epithelium hinders the riboflavin from penetrating the cornea by acting as a barrier to the diffusion of the riboflavin molecules into the cornea.
  • a production of singlet oxygen radicals introduces collagen crosslinking between collagen fibrils based on the formation of covalent and trivanent crosslinks.
  • the UV irradiation requires that either the additional UV light source is moved to the patient or the patient is moved to the additional UV light source.
  • the treatment steps are performed manually, so that, for example, a certain waiting time exists for the patient and the treating physician(s).
  • the waiting time results from a manual diagnosis of the patient, the resulting time-delayed and manual introduction or application of the photosensitizer and strengthening thereof, and again the time-delayed refractive treatment with the UV light.
  • a crosslinking control system comprises: a photosensitizer providing unit, a light source, and a control computer.
  • the photosensitizer providing unit is configured to provide photosensitizer for introduction or application of the photosensitizer into or onto tissue.
  • the light source is configured to provide light having a wavelength suitable to activate the photosensitizer introduced into or applied onto the tissue for crosslinking.
  • the control computer is programmed to determine one or more control parameters for control of at least one of the activation of the photosensitizer and the introduction or application of the photosensitizer.
  • a control program may be provided in and executable on the control computer.
  • the control program may contain instructions that, when executed by the control computer, execute control operations as described herein.
  • the control computer may be programmed to control at least one of the activation of the photosensitizer and the introduction or application of the photosensitizer by considering the determined one or more control parameters.
  • the tissue may be or comprises eye tissue, e.g., corneal tissue.
  • the crosslinking may be regarded as corneal crosslinking.
  • the tissue is not limited to eye tissue but may be or comprise all kinds of tissue.
  • the photosensitizer may comprise any suitable ingredients that stabilize corneal tissue, e.g., riboflavin (vitamin B2), lysyloxidase, transglutaminase, sugar aldehydes, ethylcarbodiimid, glutaraldehyde, formaldehyde or mixtures of these e.g., Karnovsky solution. At least some of the aforementioned photosensitizers may also be used for other tissue than eye tissue like corneal tissue.
  • the light source may be configured to provide light in a wavelength range from 360nm to 370nm for corneal crosslinking, i.e., to mitigate new intracorneal protein connections. In the wavelength range from 360nm to 370nm human cornea soaked with riboflavin is maximally absorbed.
  • photosensitizers may be conceivable in the future, which may be activated by irradiation (which may also be named illumination) with light in wavelength ranges differing from the aforementioned exemplary range(s).
  • irradiation which may also be named illumination
  • the stress of the cornea may be improved by a factor of up to 1.5.
  • the one or more control parameters for control of the activation of the photosensitizer comprise at least one of: information specifying the duration of irradiation of the photosensitizer with the light, information specifying the intensity of the light for irradiating the photosensitizer, information specifying the wavelength of the light for irradiating the photosensitizer, information specifying the spatial distribution of the light in or on the tissue, and information specifying the temporal distribution of the light in or on the tissue.
  • the information specifying the duration of irradiation of the photosensitizer with the light may be or comprise information specifying for how long the photosensitizer is to be continuously or repetitively irradiated.
  • the duration of irradiation may be or comprise one or more time periods.
  • the information specifying the spatial distribution of the light in or on the tissue may be or comprise information specifying one or more locations which are to be irradiated with the light.
  • the information specifying the intensity of the light for irradiating the photosensitizer may be or comprise information about one or more intensity profiles of the light at respective one or more locations on or in the tissue. The intensity profiles may be specified by the mean power of the light at the respective location(s) to be irradiated.
  • the information specifying the intensity may specify different intensities to be achieved at at least a subset of the multiple locations.
  • the information specifying the intensity of the light for irradiating the photosensitizer may comprise information about the maximum dose to be applied to the tissue.
  • a maximum dose (energy) of 5 J/cm 2 may be applied to the cornea.
  • the information specifying the temporal distribution of the light in or on the tissue may be or comprise information about an interval between subsequent irradiation of the photosensitizer with the light. A desired temporal distribution may be achieved by illuminating parts of the tissue sequentially with the light.
  • the mean power of the light for irradiation may be in the range of 3 to 100mW/cm 2 or higher, for example, a range of 3-10; 10-30; 30-50; 50-80; 80-100mW/cm 2 .
  • the wavelength of the light may lie within a wavelength range from 360nm to 370nm.
  • the duration of irradiation may be 30 minutes with an additional application or introduction of photosensitizer every 2 minutes. In case of riboflavin, the additional application or introduction may be necessary because of the conversion of riboflavin into lumiflavin and lumichrome under irradiance of light having a wavelength from 360nm to 370nm.
  • the one or more control parameters for control of the introduction or application of the photosensitizer comprise at least one of: information specifying the quantity of the photosensitizer to be introduced or applied into or onto the tissue, information specifying one or more positions in or on the tissue for the introduction or application of the photosensitizer, and information specifying one or more points or periods of time for the introduction or application of the photosensitizer.
  • the information specifying the quantity of the photosensitizer to be introduced or applied into or onto the tissue may be or comprise information specifying one or more dosages to be applied during one or more periods of time.
  • the one or more periods of time may also be specified by the one or more control parameters.
  • the information specifying one or more positions in or on the tissue for the introduction or application of the photosensitizer may specify one or more locations in or on the tissue at which the same or a different amount of photosensitizer can be applied or introduced.
  • the photosensitizer may be introduced into or applied onto the corneal tissue in a number of different ways.
  • an epithelial abrasion may be performed first because the epithelium may act as a barrier for the molecules of the photosensitizer.
  • At least one incision may be created in the cornea for the introduction or application of the photosensitizer into or onto the cornea as described in US 13/473,004 of the applicant, the content of which is incorporated by reference herein.
  • the at least one incision may be or may comprise at least one cut and/or at least one channel incision.
  • the at least one channel incision may be created for the introduction of photosensitizer into the cornea.
  • the at least one channel incision may form one or more channels for the introduction of photosensitizer.
  • the at least one cut may be created for the application of photosensitizer onto the cornea.
  • the at least one incision may be created by means of a laser source configured to provide laser radiation.
  • laser sources include an attosecond laser, a femtosecond laser, a nanosecond laser, or a picosecond laser.
  • Such laser sources for example, a femtosecond laser, cut tissue of the eye by photodisruption of the tissue with the energy of the laser light, which creates laser inducted optical breakthrough (LIOB), which generate cavitation bubbles.
  • LIOB laser inducted optical breakthrough
  • the laser system cuts a flap or cap in the stroma. The flap/cap is lifted or removed to ablate the exposed stroma using, e.g., an excimer laser in order to reshape the cornea.
  • Pulsed lasers with pulse lengths in the picosecond, nanosecond, femtosecond and attosecond range are suitable for creating the at least one incision, e.g., the at least one cut and/or the at least one channel incision.
  • the laser source may provide laser radiation in a wavelength range of 300-1900 nanometers (nm), for example, a wavelength in the range of 300-650, 650-1050, 1050-1250, or 1100-1900 nm.
  • the foci of the laser radiation may move along a straight or curved line to yield LIOBs in the tissue in order to produce the at least one incision, e.g., the at least one cut and/or channel incision.
  • the at least one incision may be created such that, on the one hand, the separation of the individual adjacent LIOB from each other (or “spacing" between the bubbles) may impair the structure and stability of the tissue as little as possible.
  • the separation between the LIOBs forming the at least one channel incision may be so small that the photosensitizer, introduced into the at least one channel incision in the form of a solution penetrates into the tissue through the at least one channel incision in the desired manner, i.e., from LIOB to LIOB. In the regions between adjacent LIOBs, the photosensitizer therefore penetrates by diffusion.
  • the term "channel” or "channel incision” is not necessarily to be thought of as a continuous cavity fully free of tissue, although on the other hand completely continuous channels or channel incisions can also be envisaged in certain embodiments.
  • channel or "channel incision” as used herein in certain embodiments does not mean an incision area for creating a flap/cap as in LASIK.
  • cut on the other hand, may be understood as a flap/cap, which may then be hardened by crosslinking, e.g., corneal crosslinking.
  • the at least one incision e.g., comprising at least one cut and/or at least one channel incision
  • the at least one incision may be created by dissecting the cornea by means of the laser radiation provided by the laser source.
  • photosensitizer may be introduced into the at least one channel incision and/or applied onto the at least one cut.
  • the introduced and/or applied photosensitizer may then be activated by irradiating the photosensitizer with the light.
  • control computer is programmed to control the photosensitizer providing unit to provide the photosensitizer for the introduction or application of the photosensitizer in accordance with the determined one or more control parameters.
  • the control computer is configured to instruct the photosensitizer providing unit to provide the photosensitizer in accordance with at least one of the information specifying the quantity of the photosensitizer to be introduced or applied into or onto the tissue and the information specifying one or more points or periods of time for the introduction or application of the photosensitizer It may also use the information specifying one or more positions in or on the tissue for the introduction or application of the photosensitizer.
  • the photosensitizer providing unit may further comprise a guiding device configured to guide the photosensitizer into or onto the tissue in accordance with the determined one or more control parameters.
  • the control computer may be programmed to control the light source to activate the photosensitizer in accordance with the determined one or more control parameters.
  • the control computer may be configured to instruct the light source to provide the light in accordance with at least one of the information specifying the duration of irradiation of the photosensitizer with the light, the information specifying the intensity of the light for irradiating the photosensitizer, the information specifying the wavelength of the light for irradiating the photosensitizer, the information specifying the spatial distribution of the light in or on the tissue and the information specifying the temporal distribution of the light in or on the tissue.
  • the light source may comprise or may be configured as an UV light source.
  • the light source may comprise or may be configured as at least one of one or more UV light emitting diodes (LEDs), one or more glass fibers and one or more light waveguides.
  • LEDs UV light emitting diodes
  • a plurality of UV LEDs, glass fibers or light waveguides may be provided as the light source.
  • Each of the plurality of UV LEDs, glass fibers or light waveguides may be configured to alternately deliver light or not in accordance with the instructions of the control computer.
  • the control computer may select one or more of the plurality of the UV LEDs, glass fibers or light waveguides to provide the light.
  • one or more partial areas of the tissue may be irradiated with the light.
  • the crosslinking can be selectively controlled.
  • the intensity of the light incident on the tissue may be changed.
  • the control system may further comprise a light adjustment apparatus.
  • the control computer may be programmed to control the light adjustment apparatus to adjust the light provided by the light source in accordance with the determined one or more control parameters.
  • the control computer may be configured to instruct the light adjustment apparatus to adjust or change the light provided by the light source in accordance with at least one of the information specifying the duration of irradiation of the photosensitizer with the light, the information specifying the intensity of the light for irradiating the photosensitizer, the information specifying the wavelength of the light for irradiating the photosensitizer, the information specifying the spatial distribution of the light in or on the tissue and the information specifying the temporal distribution of the light in or on the tissue.
  • the control computer may instruct the light adjustment unit to irradiate only one or more partial areas of the tissue with the light.
  • the light adjustment apparatus may comprise or may be configured as at least one of a diaphragm, a beam delimiter and a digital micromirror device (DMD) which may be suitably controlled by the control computer.
  • a diaphragm may be regarded as a thin opaque structure with an opening (aperture) at its center.
  • the role of the diaphragm is to stop the passage of light, except for the light passing through the aperture. Thus it is also called a stop (or an aperture stop).
  • a stop or an aperture stop
  • a beam delimiter may be used to adjust the light intensity, for example.
  • the DMD may be regarded as an optical semiconductor.
  • a DMD chip may have on its surface several hundred or thousand microscopic mirrors arranged in a rectangular array. The mirrors may be individually rotated, to an on or off state. In the on state, light from the light source is reflected into a lens in order to be irradiated on the tissue. In the off state, the light is directed elsewhere without irradiating the tissue, e.g., into a beam dump. In this way, a desired spatial distribution of the light may be achieved.
  • the control computer may be configured to repetitively determine at least one of the one or more control parameters.
  • at least one of the one more control parameters may be determined before a laser treatment and/or during the laser treatment and/or after the laser treatment. It is also conceivable that at least one of the one or more control parameters is repetitively, e.g., continuously, determined during the laser treatment.
  • the crosslinking control system may further comprise an acquisition apparatus configured to acquire information about the tissue before, during and/or after the application or introduction of the photosensitizer.
  • the acquisition apparatus may comprise or may be configured as at least one of an OculyzerTM, an Allegro AnalyzerTM, an Allegro TopolyzerTM, an optical biometer, an Optical Coherence Tomography (OCT) device, an optical low coherence reflectometer (OLCR), a slit lamp and an eye tracker.
  • OCT Optical Coherence Tomography
  • OCR optical low coherence reflectometer
  • the acquired information about the tissue may comprise at least one of information about the thickness of the tissue and information about the stability of the tissue.
  • the control computer may be programmed to determine, based on the acquired information about the tissue, whether crosslinking is required.
  • the control computer may be programmed to determine the one or more control parameters, if it is determined that crosslinking is required.
  • the OculyzerTM may be based on Scheimpflug technology, providing non-contact measurement and analysis of the complete anterior eye segment. Measurements may be performed from the anterior surface of the cornea to the back of the lens.
  • the Allegro AnalyzerTM may be configured to measure the complete optics of the eye and to calculate individual wavefront aberrations.
  • the Allegro TopolyzerTM may be configured to provide non-contact topography, keratometry, and pupilometry.
  • the optical biometer may be configured to capture axial eye dimensions and anterior segment measurements. Measurements may include axial length, central corneal thickness, anterior chamber depth, central lens thickness, and retina thickness. Additionally, the optical biometer may provide information concerning keratometry, white-to-white distance, and pupillometry.
  • the slit lamp may be regarded as an instrument comprising a high-intensity light source that can be focused to shine a thin sheet of light into the eye. It may be used in conjunction with a biomicroscope.
  • the slit lamp may facilitate an examination of the anterior segment, or frontal structures and posterior segment, of the human eye, which includes the eyelid, sclera, conjunctiva, iris, natural crystalline lens, and cornea.
  • a binocular slit lamp examination may provide a stereoscopic magnified view of the eye structures in detail, enabling anatomical diagnoses to be made for a variety of eye conditions.
  • An eye tracker may be configured to track eye movements.
  • the control computer may be programmed to determine whether crosslinking is required for the respective tissue.
  • the control computer may be configured to determine a result of the crosslinking based on the information about the tissue.
  • the control computer may determine, based on the information about the tissue, whether (further) application or introduction of the photosensitizer onto or into the cornea and/or whether (further) irradiation of the photosensitizer with the light is necessary. If it is determined by the control computer that (further) crosslinking is required, the control computer may determine the one or more control parameters (again).
  • the crosslinking control system may further comprise an output unit to output the determined one or more control parameters.
  • the output may in this way be considered by a treating physician. If the treating physician agrees with the (recommended) control parameters(s) as being output by the output unit, he/she can approve the output and the control computer uses the approved control parameter(s) for the control.
  • the treating physician may also change one or more of the output (recommended) parameter(s) and the control computer may use the changed set of control parameters for control.
  • the crosslinking control system may be connectable to a computer network or a server to retrieve data from and/or store data in the computer network or the server.
  • crosslinking control system as described herein for control of crosslinking in tissue is described.
  • the laser system comprises: a crosslinking control system as described herein and a laser apparatus configured to irradiate tissue with laser radiation.
  • Fig. 1 illustrates an example of a laser system 100 comprising a crosslinking control system according to a first embodiment.
  • the crosslinking control system comprises a photosensitizer providing unit 10 which in the following will be referred to as riboflavin dispensing unit 10 because, in the present example for sake of explanation rather than limitation, riboflavin is used by way of example as a photosensitizer and the photosensitizer providing unit 10 is not only configured to provide photosensitizer but also to dispense the photosensitizer.
  • the laser system 100 further comprises a guiding device 12.
  • the guiding device 12 may be part of the riboflavin dispensing unit 10 or may be a separate unit.
  • the guiding device 12 is configured to guide the riboflavin provided by the riboflavin dispensing unit 10 at intended locations as will be described in more detail below.
  • the crosslinking control system comprises a light source 20.
  • the light source comprises, by way of example, an UV light source 22 configured to provide light 24 in the UV spectrum, which is sometimes in the following also referred to as UV light 24 .
  • the light source 20 comprises a slit lamp 26 providing high-intensity light 28 as an example of a part of an acquisition apparatus.
  • the light source 20 does not comprise any acquisition apparatus or comprises different components in the acquisition apparatus than the slit lamp 26, i.e., the slit lamp 26 is optional only.
  • the light source 20 may comprise only the UV lamp 22.
  • the acquisition apparatus e.g., comprising the slit lamp 26, is arranged somewhere else than as a part of the light source 20.
  • the slit lamp 26 provides high-intensity light 28 to facilitate an examination of the anterior segment, or frontal structures and posterior segment, of the eye the patient 60.
  • the crosslinking control system comprises a control computer 30.
  • the control computer 30 comprises separate control units, namely a riboflavin control unit 32, a lamp control unit 34 and a laser control unit 36.
  • the riboflavin control unit 32 is configured to control the riboflavin dispensing unit 10 and/or the guiding device 12.
  • the lamp control unit 34 is configured to control the light source 20.
  • the lamp control unit 24 may be configured to control the UV light source 22 and the slit lamp 26 independently from each other.
  • the laser control unit 36 is configured to control a laser source 50 providing excimer laser radiation or ultrashort-pulsed laser radiation.
  • Ultrashort may be regarded as specifying pulse duration within the nanosecond, picosecond or femtosecond or attosecond range.
  • the riboflavin control unit 32, the lamp control unit 34 and the laser control unit 36 may also be contained in the control computer 30 as one single control unit rather than as separate control units.
  • the control computer may only comprise one or more of the riboflavin control unit 32 and the lamp control unit 34.
  • the laser control unit 36 may be arranged independently from the control computer 30 in the laser system 100. Information acquired by an additional camera system may be considered in the control computer in order to control one or more of the components of the laser system 100.
  • UV light source 22 and the laser source 50 are shown as separate units for providing radiation with different characteristics, it is also conceivable that only one radiation source is provided, which is configured to provide suitable radiation.
  • the radiation may then be controlled such that it is suitable for both creating, in tissue, at least one incision for the introduction or application of photosensitizer into or onto the tissue, and activating the photosensitizer for corneal crosslinking.
  • the riboflavin control unit 32 is configured to control at least one of the riboflavin dispensing unit 10 and the guiding device 12
  • the lamp control unit 34 is configured to control the light source 20
  • the laser control unit 36 is configured to control the laser source 50, e.g., an excimer or femtosecond laser, as will be described in more detail below.
  • the control computer 30 is connected to a separate computer network, which is herein referred to as WaveNetTM 40.
  • the connection may be a wireless or wired data connection.
  • the latter is shown in Fig. 1 by way of example.
  • an interface is provided to allow access to practice-specific electronic medical records upon request.
  • treatment parameters can be transferred to and from the laser system 100.
  • the patient 60 to be treated is arranged on a bedchair or patient bed 70 of the laser system 100.
  • the control computer 30 is configured to determine one or more control parameters for control of one or more of the components of the crosslinking control system and/or the laser system 100.
  • the control computer 30 is, by way of example, configured to control the riboflavin dispensing unit 10 (by means of the riboflavin control unit 32), to control the guiding device 12, to control the light source 20 (by means of the lamp control unit 34), and to control the laser source 50 (by means of the laser control unit 36).
  • the control computer 30 may consider the information of the patient's eye illuminated by the slit lamp 26 and acquired by further components, e.g., a camera system, in order to determine the one or more control parameters.
  • control parameters of Fig.2 are shown in Fig.2 with respect to an ongoing laser surgical treatment of an eye.
  • the control parameters of Fig. 2 are determined with reference to treatment of corneal abrasion as one example of laser surgical treatment.
  • Corneal abrasion is a medical condition involving the loss of the surface epithelial layer of the eye's cornea.
  • the control computer 30 is configured to determine the photosensitizer to be used. For this purpose, the control computer 30 may instruct an acquisition apparatus to acquire information about the pre-operative thickness of the cornea. If the pre-operative thickness of the cornea is smaller than 400 ⁇ m, the control computer 30 may recommend hypoosmolar riboflavin. If, however, the pre-operative thickness of the cornea is larger than 400 ⁇ m, the control computer 30 may recommend isoosmolar riboflavin.
  • the control computer 30 computes a concentration of riboflavin to be introduced into or applied onto the cornea. For example, the control computer 30 recommends a concentration of 0.1%.
  • the control computer 30 further computes a recommended diffusion time indicating how long riboflavin shall be introduced into or applied onto the cornea. In the example shown in Fig. 2 , the control computer 30 exemplarily computes a diffusion time of 30 minutes.
  • the control computer 30 may consider information about the thickness of the cornea (or other information about the eye tissue) and information about the recommended photosensitizer.
  • the control computer 30 computes a recommended wavelength of UV light for irradiation of the recommended photosensitizer.
  • absorption characteristics over the wavelength may be stored in the control computer 30 or in the 40. These absorption characteristics may then be retrieved by the control computer 30 in order to determine a wavelength suitable to activate the recommended photosensitizer.
  • Fig. 4 For riboflavin. As can be seen therefrom, riboflavin has an absorption maximum at 370nm. In consequence, if riboflavin is used as the photosensitizer, the control computer may recommend a wavelength of 370nm for irradiation of the riboflavin.
  • the control computer 30 calculates a recommended intensity of light 24 for irradiation of the riboflavin, which is called irradiance in Fig. 2 .
  • irradiance a recommended intensity of light 24 for irradiation of the riboflavin
  • 3mW/cm 2 may be recommended by the control computer 30.
  • the control computer 30 may determine the irradiance by considering information about the thickness of the cornea (or other information about the eye tissue), information about the recommended photosensitizer and information about the recommended wavelength.
  • control computer 30 computes a recommended treatment time indicating how long the introduced or applied riboflavin is to be irradiated with the light 24.
  • the control computer 30 exemplarily computes a treatment time of 30 minutes.
  • the control computer 30 may consider information about the thickness of the cornea (or other information about the eye tissue), information about the recommended photosensitizer and/or information about the recommended wavelength and irradiance of the light 24.
  • the control parameters shown in Fig. 2 are purely exemplary and different or further control parameters may be determined and recommended by the control computer 30.
  • the control computer 30 After determining the exemplary control parameters as given in Fig. 2 and as explained above with reference to Fig. 2 , the control computer 30 outputs the determined control parameters as a recommendation on an output unit, e.g., a display or the like.
  • the treating physician may approve the recommended control parameters or may change one or more of the recommended control parameters, for example, by means of a touch input on the display. If one or more of the control parameters are changed by the treating physician, the control computer may adjust at least some of the other control parameters by considering the changes input by the treating physician.
  • the control computer controls the riboflavin dispensing unit 10, the guiding device 12 and the light source 20 in accordance with the set control parameters.
  • control computer 30 may instruct the riboflavin dispensing unit 10 to dispense hypoosmolar riboflavin with a concentration of 0.1% and a diffusion time of 30 minutes.
  • the control computer 30 may instruct the guiding device 12 to guide the riboflavin as dispensed by the riboflavin dispensing unit 10 to specific locations into or onto the cornea.
  • the control computer 30 may instruct the UV light source 22 of the light source to provide light with a wavelength of 370nm and an irradiance of 3mW/cm 2 on the tissue to be irradiated during a treatment time of 30 minutes.
  • Fig. 3 shows how some of the exemplary treatment parameters are used for irradiation.
  • the control computer 30 instructs the UV light source 22 to irradiate a circle-shaped area (crosslinking area) with a diameter of 8mm. Further, the control computer 30 instructs the UV light source 22 to provide UV light 24 having a wavelength of 370nm. The control computer 30 further instructs the UV light source 22 to generate UV light 24 with an irradiance of 3 mW/cm 2 on the crosslinking area to be irradiated.
  • a top hat shaped profile 80a as shown on the left side of Fig. 5 can be used or a donut like distribution 80b as shown on the right side of Fig. 5 can be used.
  • a donut like distribution 80b as shown on the right side of Fig. 5 can be used.
  • different areas or volumes within the eye can be irradiated to create different crosslinked volumes within the eye.
  • Fig. 6 shows another example of a laser system 200 comprising a crosslinking control system according to a second embodiment.
  • the crosslinking control system according to the second embodiment basically corresponds to the crosslinking control system according to the first embodiment.
  • the crosslinking control system according to the second embodiment does not comprise a slit lamp 26 (cf. Fig. 1 ).
  • an UV light source 22 is also provided in the second embodiment.
  • the crosslinking control system of the second embodiment has one single control computer 30 and additionally comprises a Digital Light Processing (DLP)-DMD device 90 and an eye tracker 94.
  • DLP Digital Light Processing
  • eye movements during surgery may be compensated by the use of the eye tracker to follow the eye movement.
  • the control computer may consider the eye movement data for determining the one or more control parameters. If eye movement is not considered, the eye movement may interfere with the intended crosslinking area, which may result in the crosslinking area being larger and non-symmetric due to the eye movements. However, if the eye movements are followed and considered by the control computer 30, exact application of the UV light 24 can be achieved.
  • control computer 30 may consider the eye movement data to determine the spatial distribution of the light 24.
  • control computer 30 may slightly adjust the spatial distribution of the light 24 based on the movement of the eye 80. In this way, at least almost the same crosslinking area can be irradiated despite the movements of the eye 80.
  • the eye tracker may follow translation movements of the eye in the x-y-z direction, rotational movements of the eye in the x-y-direction as well as eye torsion, i.e., cyclotrosion.
  • the DLP-DMD device 90 serves as another example of a light adjustment apparatus.
  • the DMD concept is briefly explained with respect to Figs. 7a and 7b .
  • Fig. 7a light provided by a light source 20 and incident on one DMD element 90a, is reflected in dependence of the state of the DMD element 90a.
  • Each DMD element is typically formed by a mirror.
  • the light can be reflected on a light dump 92.
  • the foregoing may also be referred to as the off state of the DMD element 90a.
  • the light can be reflected on a projection lens.
  • a typical DMD device normally comprises a plurality, e.g., several hundred or several thousand, of DMD elements 90a.
  • the DLP-DMD device 90 may comprise 1000x1000 or even more DMD elements 90a.
  • the DLP-DMD device 90 (DLP-DMD chip 90) may comprise even up to millions of DMD elements 90a configured as tiny, microscopic mirrors which reflect light digitally.
  • Each of these DMD elements 90a of one DLP-DMD device 90 (which may also be referred to as DLP-DMD chip 90) can be controlled and tilted independently from each other.
  • each individual DMD element 90a can be switched on (into its on state) or off (into its off state) by applying a voltage to an address electrode of the DMD element 90a.
  • the spatial distribution of the UV light 24 can be precisely controlled by means of the DLP-DMD device 90 according to the instructions received from the control computer 30.
  • the DLP-DMD device 90 may act as a light shaping device for individually shaping the UV light 24 to any desired pattern or shape.
  • the control computer 30 can instruct each of the DMD elements 90a of the DLP-DMD device 90 to move to a specific tilt angle, in order to irradiate the eye 80 with the intended spatial distribution as computed by the control computer 30 or as input by a treating physician.
  • the control computer 30 may consider the eye movement data acquired by the eye tracker 94.
  • the control computer 30 may then instruct the UV light source 22 and the DLP-DMD device 90 accordingly.
  • the control computer 30 may instruct the UV light source 22 and the DLP-DMD device 90 to shape the intensity profile and the spatial distribution in the desired manner.
  • the control computer 30 may instruct an x-y scanner to move the UV light 24 in accordance with the eye movements.
  • the control computer 30 determines one or more control parameters, e.g., the control as shown in Fig. 2 .
  • the control computer 30 instructs the UV light source 22 to irradiate UV light 24 in accordance with the determined control parameters, for example, UV light having a wavelength of 370nm and an irradiance on the patient's eye of 3mW/cm 2 .
  • the control computer 30 also determines a recommended spatial distribution and, when the spatial distribution is approved by the treating physician, instructs the DMD elements 90a of the DLP-DMD device 90 to assume certain tilt angles respectively.
  • the UV light 24 is guided to the DLP-DMD device 90and is partially either reflected on the beam dump 92 or via an x-y scanner and beam combiner 98 on the patient's eye 80.
  • the x-y scanner 96 is used to compensate the movement of the patient's eye 80, which was detected by eye tracker 94 and controlled by the control computer 30.
  • the control computer 30 may further determine a treatment time of 30 minutes. During this treatment time, the patient's eye 80 is irradiated with the UV light 24.
  • the eye tracker 94 repetitively, e.g., continuously, tracks the movement of the patient's eye 80 and forwards the acquired movement data to the control computer 30.
  • the control computer 30 can then adjust one or more of the control parameters on the basis of the movement data.
  • the control computer may instruct at least some of the DMD elements 90a to change their tilt angles.
  • the UV light 24 may irradiate the patient's eye with the intended spatial distribution despite of the eye movement.
  • an individual beam shape profile of the UV light 24 may be formed. This may facilitate activating the photosensitizer locally at certain points or areas. In this way, the eye tissue can be precisely hardened in the way desired by the treating physician or required by the laser treatment to be or already being performed.
  • the hardened cornea may then be treated with laser radiation provided by a laser source (not shown but part of component arrangement 96).
  • the component arrangement 96 may further comprise the x-y scanner and a focus lens to guide and focus the laser radiation.
  • the laser radiation can then irradiate the eye 80 to perform any conceivable laser treatment of the eye like LASIK, IntraLASIK, photorefractive keratectomy (PRK, LASEK), laser thermal keratoplasty or phototherapeutic keratectomy (PTK).
  • a method embodiment for laser treatment 800 is shown in the flowchart of Fig. 8 .
  • one or more control parameters may be determined by the control computer 30, as described herein, before laser treatment is performed.
  • laser radiation is provided by a laser source (step 804) and the eye tissue is irradiated with the laser radiation to perform laser treatment (step 806).
  • one or more control parameters may be determined or adjusted by the control computer 30, as described herein.
  • riboflavin may be introduced into the cornea or applied onto the cornea and the eye tissue may be irradiated with the UV light in accordance with the one or more determined or adjusted control parameters (step 808) to perform crosslinking.
  • the steps 802 and 808 may be regarded as steps of a crosslinking control method.
  • information about the tissue may be acquired by an acquisition apparatus in a further optional step 810 before, during and/or after the treatment.
  • the control computer 30 may determine whether the treatment was successful.
  • the step 810 may also be a step of the crosslinking control method.
  • Fig. 9a corneal crosslinking increases drastically the stress on the corneal tissue.
  • the best results are achieved by means of anterior treated flaps (see Fig 9b ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Electromagnetism (AREA)
  • Laser Surgery Devices (AREA)

Claims (14)

  1. Vernetzungssteuerungssystem zur Hornhautvernetzung, umfassend:
    - eine Photosensibilisator bereitstellende Einheit (10), die ausgestaltet ist, um Photosensibilisator zur Einbringung oder Applikation des Photosensibilisators in oder auf Gewebe bereitzustellen, wobei das Gewebe Augengewebe eines Auges umfasst;
    - eine Lichtquelle (20), die ausgestaltet ist, um Licht mit einer geeigneten Wellenlänge bereitzustellen, um den in das Gewebe eingebrachten oder auf das Gewebe applizierten Photosensibilisator zur Vernetzung zu aktivieren; und
    - einen Steuerungscomputer (30), der programmiert ist, um einen oder mehrere Steuerungsparameter zur Steuerung der Aktivierung des Photosensibilisators und der Einbringung oder Applikation des Photosensibilisators zu bestimmen,
    dadurch gekennzeichnet, dass
    der eine oder die mehreren Steuerungsparameter zur Steuerung der Einbringung oder Applikation des Photosensibilisators mindestens eins von Informationen, die die Menge des in oder auf das Gewebe einzubringenden oder zu applizierenden Photosensibilisators spezifizieren, und Informationen, die einen oder mehrere Zeitpunkte oder Zeiträume für die Einbringung oder Applikation des Photosensibilisators spezifizieren, umfasst bzw. umfassen.
  2. Vernetzungssteuerungssystem nach Anspruch 1, des Weiteren umfassend:
    - einen Erfassungsapparat (94), der ausgestaltet ist, um Informationen zu dem Gewebe vor, während und/oder nach der Applikation oder Einbringung des Photosensibilisators zu erfassen,
    wobei der Erfassungsapparat einen Augen-Tracker (94) umfasst, der ausgestaltet ist, um Augenbewegungen des Auges zu bestimmen und entsprechende Augenbewegungsdaten an den Steuerungscomputer (30) zu übertragen, und wobei der Steuerungscomputer (30) ausgestaltet ist, um die Augenbewegungsdaten zur Bestimmung des einen oder der mehreren Steuerungsparameter zu berücksichtigen.
  3. Vernetzungssteuerungssystem nach Anspruch 1, wobei der eine oder die mehreren Steuerungsparameter zur Steuerung der Aktivierung des Photosensibilisators mindestens eins von Informationen, welche die Dauer der Bestrahlung des Photosensibilisators mit dem Licht spezifizieren, Informationen, welche die Intensität des Lichts zum Bestrahlen des Photosensibilisators spezifizieren, Informationen, welche die Wellenlänge des Lichts zum Bestrahlen des Photosensibilisators spezifizieren, Informationen, welche die räumliche Verteilung des Lichts in oder auf dem Gewebe spezifizieren, und Informationen, welche die zeitliche Verteilung des Lichts in oder auf dem Gewebe spezifizieren, umfasst bzw. umfassen.
  4. Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 3, wobei der eine oder die mehreren Steuerungsparameter zur Steuerung der Einbringung oder Applikation des Photosensibilisators Informationen umfasst bzw. umfassen, die eine oder mehrere Positionen in oder auf dem Gewebe zur Einbringung oder Applikation des Photosensibilisators spezifizieren.
  5. Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 4, wobei der Steuerungscomputer (30) programmiert ist, um mindestens eins von der Aktivierung des Photosensibilisators und der Einbringung oder Applikation des Photosensibilisators unter Berücksichtigung des bestimmten einen oder der bestimmten mehreren Steuerungsparameter zu steuern; und/oder wobei der Steuerungscomputer (30) programmiert ist, um die Photosensibilisator bereitstellende Einheit (10) zu steuern, um den Photosensibilisator für die Einbringung oder Applikation des Photosensibilisators gemäß dem bestimmten einen oder den bestimmten mehreren Steuerungsparametern bereitzustellen.
  6. Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 4, wobei der Steuerungscomputer (30) des Weiteren programmiert ist, um die Lichtquelle (20) zu steuern, um den Photosensibilisator gemäß dem bestimmten einen oder den bestimmten mehreren Steuerungsparametern zu aktivieren; und/oder wobei das Steuerungssystem des Weiteren einen Lichtjustierungsapparat (90) umfasst, wobei der Steuerungscomputer (30) programmiert ist, um den Lichtjustierungsapparat (90) zu steuern, um den Photosensibilisator gemäß dem bestimmten einen oder den bestimmten mehreren Steuerungsparametern zu aktivieren.
  7. Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 5, wobei der Steuerungscomputer (30) programmiert ist, um den Lichtjustierungsapparat (90) zu steuern, um mindestens eins von der Dauer der Bestrahlung des Photosensibilisators mit dem Licht, der Intensität des Lichts zur Bestrahlung des Photosensibilisators, der Wellenlänge des Lichts zur Bestrahlung des Photosensibilisators, der räumlichen Verteilung des Lichts in oder auf dem Gewebe und der zeitlichen Verteilung des Lichts in oder auf dem Gewebe gemäß dem bestimmten einen oder den bestimmten mehreren Steuerungsparametern zu verändern.
  8. Vernetzungssteuerungssystem nach Anspruch 7, wobei der Lichtjustierungsapparat (90) mindestens eines von einem Diaphragma, einem Strahlbegrenzer und einer digitalen Mikrospiegelvorrichtung umfasst.
  9. Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 8, wobei der Steuerungscomputer (30) ausgestaltet ist, um wiederholt den einen oder die mehreren Steuerungsparameter zu bestimmen; und/oder
    wobei die Photosensibilisator bereitstellende Einheit (10) des Weiteren eine Führungsvorrichtung (12) umfasst, die ausgestaltet ist, um den Photosensibilisator gemäß dem bestimmten einen oder den bestimmten mehreren Steuerungsparametern in oder auf das Gewebe zu führen.
  10. Vernetzungssteuerungssystem nach Anspruch 2, wobei der Erfassungsapparat (26, 94) mindestens eines von einem Oculyzer, einem Analysator, einem Topolyzer, einem optischen Biometer, einer optischen Kohärenztomographievorrichtung und einer Spaltlampe umfasst; und/oder
    wobei die erfassten Informationen zu dem Gewebe mindestens eines von Informationen zu der Dicke des Gewebes und Informationen zu der Stabilität des Gewebes umfassen.
  11. Vernetzungssteuerungssystem nach Anspruch 2 oder 10, wobei der Steuerungscomputer (30) programmiert ist, um basierend auf den erfassten Informationen zu dem Gewebe zu bestimmen, ob Vernetzung erforderlich ist, und falls bestimmt wird, dass Vernetzung erforderlich ist, den einen oder die mehreren Steuerungsparameter zu bestimmen; und/oder
    wobei der Steuerungscomputer (30) programmiert ist, um ein Ergebnis der Vernetzung basierend auf den Informationen zu dem Gewebe zu bestimmen.
  12. Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 11, wobei das Vernetzungssteuerungssystem des Weiteren eine Ausgabeeinheit umfasst, um den bestimmten einen oder die bestimmten mehreren Steuerungsparameter auszugeben; und/oder
    wobei die Lichtquelle (20) mindestens eine von einer Ultraviolett-, UV, Lichtquelle (22), einer oder mehreren UV-Licht emittierenden Dioden, LEDs, einer oder mehreren Glasfasern und einem oder mehreren Lichtwellenleitern umfasst oder als solche ausgestaltet ist.
  13. Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 12, wobei das Vernetzungssteuerungssystem mit einem Computernetzwerk (40) oder einem Server verbindungsfähig ist, um Daten aus dem Computernetzwerk oder dem Server abzurufen und/oder diese dort zu speichern.
  14. Lasersystem (100), umfassend:
    - ein Vernetzungssteuerungssystem nach einem der Ansprüche 1 bis 13; und
    - einen Laserapparat (50), der ausgestaltet ist, um Gewebe mit Laserstrahlung zu bestrahlen.
EP13788721.2A 2013-10-30 2013-10-30 Vernetzungssteuerung Active EP3062750B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/072710 WO2015062648A1 (en) 2013-10-30 2013-10-30 Crosslinking control

Publications (2)

Publication Number Publication Date
EP3062750A1 EP3062750A1 (de) 2016-09-07
EP3062750B1 true EP3062750B1 (de) 2021-04-21

Family

ID=49552344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13788721.2A Active EP3062750B1 (de) 2013-10-30 2013-10-30 Vernetzungssteuerung

Country Status (8)

Country Link
US (1) US10828506B2 (de)
EP (1) EP3062750B1 (de)
KR (1) KR101862364B1 (de)
CN (1) CN105682620B (de)
AU (1) AU2013404375B2 (de)
CA (1) CA2924775C (de)
ES (1) ES2871378T3 (de)
WO (1) WO2015062648A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
WO2013148896A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
EP2830637A4 (de) 2012-03-29 2016-03-16 Cxl Ophthalmics Llc Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit oxidativem stress
EP3324973B1 (de) 2015-07-21 2020-06-03 Avedro, Inc. Augenbehandlung mit einem photosensibilisator
US10180248B2 (en) 2015-09-02 2019-01-15 ProPhotonix Limited LED lamp with sensing capabilities
EP3442481B1 (de) 2016-04-13 2023-06-28 Avedro, Inc. Systeme zur abgabe von arzneimitteln an ein auge
CN106236372A (zh) * 2016-08-17 2016-12-21 浙江大学 一种数字化角膜交联调节角膜曲率半径的方法及设备
WO2018063137A1 (en) * 2016-09-27 2018-04-05 Yichieh Shiuey Systems, device, and method for cross-linking corneal tissue
RU172763U1 (ru) * 2016-12-19 2017-07-21 Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" Устройство-4 для ультрафиолетового сшивания роговицы глаза
CN106693205B (zh) * 2016-12-23 2019-04-19 中国科学院苏州生物医学工程技术研究所 核黄素紫外胶联机构
CN106621063B (zh) * 2016-12-23 2019-05-14 中国科学院苏州生物医学工程技术研究所 具有眼球位置实时追踪的核黄素紫外胶联装置
CN107239050A (zh) * 2017-01-23 2017-10-10 谢圣超 一种基于互联网的眼科用手持式交联治疗控制系统
CA3084088A1 (en) * 2017-12-04 2019-06-13 Ellex Medical Pty Ltd Photobiomodulation device for treating retinal disease
KR20200139161A (ko) * 2018-03-02 2020-12-11 렌사르, 인크. 노안을 다루고, 완화시키고 역전시키기 위한 레이저 방법 및 시스템
EP3761927B1 (de) * 2018-03-05 2024-01-31 Avedro, Inc. System zur augenverfolgung während der augenbehandlung
CN108744293B (zh) * 2018-05-29 2019-06-04 清华大学深圳研究生院 一种用于图像化角膜交联的数字化光学装置
CN109157748A (zh) * 2018-09-13 2019-01-08 清华大学深圳研究生院 一种用于角膜交联的智能系统及控制方法
CA3112937A1 (en) * 2018-09-19 2020-03-26 Avedro, Inc. Systems and methods treating for corneal ectatic disorders
FR3086164A1 (fr) * 2018-09-20 2020-03-27 Keranova Procede et dispositif de determination d'une valeur minimale d'energie laser necessaire a la formation d'une bulle de gaz
US11484200B2 (en) * 2019-03-14 2022-11-01 Rxsight, Inc. Light-adjustable lens illumination system with fovea protection
CN110314035B (zh) * 2019-08-08 2022-02-11 南京市第一医院 一种形状深度可控的角膜交联装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116306A2 (en) * 2010-03-19 2011-09-22 Avedro, Inc. Systems and methods for applying and monitoring eye therapy
WO2012167260A2 (en) * 2011-06-02 2012-12-06 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence
US20130116757A1 (en) * 2010-05-07 2013-05-09 Christoph Russmann Method and device for stabilizing the cornea

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427725T1 (de) * 2004-02-03 2009-04-15 Iroc Ag Ophtalmologische vorrichtung
WO2009073213A1 (en) * 2007-12-05 2009-06-11 Avedro, Inc. Eye therapy system
DE102008046834A1 (de) * 2008-09-11 2010-03-18 Iroc Ag Steuerprogramm zum Steuern elektromagnetischer Strahlung für eine Quervernetzung von Augengewebe
EP2531260A2 (de) * 2010-02-01 2012-12-12 Montefiore Medical Center Verfahren und vorrichtungen zur hornhautkollagenvernetzung und zur behandlung von augenleiden
JP5845286B2 (ja) * 2011-01-12 2016-01-20 ソーフト イタリア エスピーエー 円錐角膜治療のためのイオン導入によるリボフラビンの角膜送達装置及び方法
WO2013059837A2 (en) * 2012-07-16 2013-04-25 Avedro, Inc. Systems and methods for corneal cross-linking with pulsed light

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116306A2 (en) * 2010-03-19 2011-09-22 Avedro, Inc. Systems and methods for applying and monitoring eye therapy
US20130116757A1 (en) * 2010-05-07 2013-05-09 Christoph Russmann Method and device for stabilizing the cornea
WO2012167260A2 (en) * 2011-06-02 2012-12-06 Avedro, Inc. Systems and methods for monitoring time based photo active agent delivery or photo active marker presence

Also Published As

Publication number Publication date
US20160236006A1 (en) 2016-08-18
CN105682620A (zh) 2016-06-15
KR101862364B1 (ko) 2018-05-29
ES2871378T3 (es) 2021-10-28
AU2013404375A1 (en) 2016-04-07
AU2013404375B2 (en) 2017-08-03
CA2924775C (en) 2020-03-31
US10828506B2 (en) 2020-11-10
CA2924775A1 (en) 2015-05-07
EP3062750A1 (de) 2016-09-07
KR20160078463A (ko) 2016-07-04
CN105682620B (zh) 2019-02-22
WO2015062648A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
EP3062750B1 (de) Vernetzungssteuerung
DK2948113T3 (en) APPARATUS FOR CORNAL CROSS BINDING
JP5184888B2 (ja) 老視の１つ又は複数の症状を防止又は遅らせるレーザ装置
KR102080336B1 (ko) 레이저 광축동을 이용하여 시력을 개선하는 장치 및 방법
US8991401B2 (en) Processes and apparatus for preventing, delaying or ameliorating one or more symptoms of presbyopia
JP2013525014A (ja) 集学的方法を用いた眼組織の処置のための方法および装置
US20130310728A1 (en) Device for dissecting an eye for the introduction of photosensitizer and method of refractive surgery
US10548771B2 (en) Device and procedure to treat presbyopia
US20230157880A1 (en) Reducing retinal radiation exposure during laser surgery
WO2017087972A1 (en) Processes and apparatus for preventing, delaying or ameliorating one or more symptoms presbyopia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200121

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALCON INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201125

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013077042

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1383856

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210515

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1383856

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210421

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210421

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2871378

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210721

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210821

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210722

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210721

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210823

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013077042

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210821

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211030

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131030

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230921

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230921

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231103

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230926

Year of fee payment: 11

Ref country code: DE

Payment date: 20230919

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240127

Year of fee payment: 11